A2A AR Agonists as Adjunct Therapy Against S. aureus Sepsis

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$132,798.00
Award Year:
2006
Program:
STTR
Phase:
Phase I
Contract:
1R41AI071496-01
Agency Tracking Number:
AI071496
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
ADENOSINE THERAPEUTICS, LLC
310 FOURTH STREET NE, SUITE 201, CHARLOTTESVILLE, VA, 22902
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
JAYSON RIEGER
(434) 951-9484
JRIEGER@ADENRX.COM
Business Contact:
SANDRA ABBOTT
(434) 220-9400
sabbott@adenrx.com
Research Institution:
UNIVERSITY OF VIRGINIA

UNIVERSITY OF VIRGINIA
BOX 400195
CHARLOTTESVILLE, VA, 22904

Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): This is a phase I STTR application to study the efficacy of selective adenosine A2A receptor (A2AR) agonists developed in the laboratories of Adenosine Therapeutics (ATL) in models of Gram-positive bacterial sepsis which will be conducted in the University of Virginia (UVA) laboratories of Dr. Michael Scheld, an expert in the field of infectious disease. Sepsis syndrome is the 11th leading cause of death in the United States. Nearly 900,000 cases occur annually, resulting in 210,000 deaths, with 50% of sepsis cases due to Gram-negative pathogens such as S. aureus. While many new therapies targeting aspects of the inflammatory cascade have been tried, the results have been generally disappointing. We hypothesize that following the initiation of sepsis syndrome, selective adenosine A2A receptor (A2AR) agonists afford protection from tissue injury and the deleterious effects of inflammation by inactivating inflammatory hematopoeitic cells (neutrophils, monocytes, macrophages and T cells). This results in reduced neutrophil-endothelial cell interactions, thus abrogating the early cascade of pro-inflammatory cytokine release with an accentuation of an anti-inflammatory cytokine- chemokine response. We will specifically evaluate 1) the pharmacokinetics and formulation stability of 3 new, highly selective and potent A2AR agonists; 2) evaluate these compounds in a lethal murine model of sepsis using S. aureus; and 3) evaluate the cytokine profile of control and drug-treated animals to gain greater understanding of underlying mechanisms and signaling molecules in sepsis. These objectives directly relate to the mission of the National Institute of Allergy and Infectious Diseases, which is to conduct and support basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases, by targeting drug development for gram-positive sepsis, for which current therapies are not ideal for patient care and survival

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government